45 results about "Targeted microbubbles" patented technology

The invention discloses a microfluidic chip and a cell screening method for screening specific cells. The chip comprises a substrate, a cavity and an acoustic excitation source, wherein the cavity comprises a middle channel, an inlet and an outlet; the acoustic excitation source is positioned on the substrate and at two sides of the middle channel and comprises two parts which extend to a direction of the outlet along the middle channel, wherein the corresponding acoustic resonance frequency of the second part close to the outlet is integer multiples of the corresponding acoustic resonance frequency of the first part far away from the outlet. Based on an acoustic streaming effect formed by targeted microbubbles and asymmetric sound fields, the microbubbles are adhered to the surfaces of the specific cells, so that the enriched cells which flow past the first part can still move in a straight line and cannot diffuse due to a laminar flow characteristic of microfluidics, and the specific cells bonded with the targeted microbubbles can shift because the acoustic resonance frequency of the second part is different from that of the first part. Thus, the screening of the specificity of the specific cells in blood is realized.

Devices, systems, and methods manipulate target materials within fluids, and may be useful for removing microbubbles and other materials from blood. Ultrasound or acoustic filtering waves may be directed across a flow of blood, and differences in density between the target microbubbles and the blood may enhance separation by driving the lighter matter upward for removal from the blood stream. A disposable acoustically transmissive conduit can replaceably engage an ultrasound transmitter to facilitate sterilization. Exemplary conduits have elongate lumen cross-sections and an axial path resembling a portion of a Mobius strip.

Compositions and methods for detecting various disorders with targeted microbubbles are disclosed. Specifically, microbubbles comprising glycoprotein Ib (GPIb), ligands for VCAM-1, and ligands for P-selectin such as PSGL-1 are disclosed. Also disclosed are methods for using targeted microbubbles to detect cardiovascular disease comprising administering the disclosed microbubbles to a subject and detecting the microbubbles in the vasculature using ultrasound.

The invention provides a hepatic carcinoma targeted photo-thermal therapeutic agent as well as a preparation method and an application thereof and belongs to the field of biomedical engineering. The hepatic carcinoma targeted photo-thermal therapeutic agent is prepared with the method comprising the following steps: (1) preparing biotinylation nanometer microbubbles; (2) preparing a Cy7 fluorescently-labeled biotinylation anti-GPC3 (glypican3) antibody; (3) preparing biotinylation RGO (reduced graphene oxide); (4) coupling the products prepared in the step (1), step (2) and step (3) through a biotin-avidin system to obtain the hepatic carcinoma targeted photo-thermal therapeutic agent. The hepatic carcinoma targeted photo-thermal therapeutic agent has ultrasonic and fluorescence imaging functions, mediates RGO targeted delivery with an ultrasound-targeted microbubble destruction technology, monitors a photo-thermal therapeutic process in real time, can be used for preparing drugs for hepatic carcinoma therapy and has excellent clinical application value.

The invention discloses a GDNF-carrying microbubble preparation and a method for making the same. The GDNF-carrying microbubble is composed of a lipid bilayer internally wrapping biological inert gas and biotinylated GDNF connected to the outside of the lipid bilayer. Employing MRI real-time guided low-frequency focused ultrasound combined with BBB opening by the GDNF-carrying microbubble to irradiate a craniocerebral parietal cortex area of a rat (the optimal parameters are set to be: probe frequency 1 Hz, microbubble 0.5 mL, irradiation period 60 s, sound pressure 0.8 MPa, and time-delay 60s) can promote GDNF to penetrate the BBB and increase the effective drug concentration of GDNF in the central nervous system. The pharmacological research after effective macromolecule breaking through of BBB by low-frequency focused ultrasound combined with target microbubble technique will further increase the advantage of neurotrophic factors in treatment of brain diseases and provide the scientific evidence for GDNF to treat nervous centralis diseases.

The invention discloses an acoustic radiation force enhanced inflammatory cell induced atherosclerosis biomimetic microbubble complex enriching and targeting system. An inflammatory cell induced atherosclerosis biomimetic microbubble complex comprises a CD11b targeting microbubble and an inflammatory cell which are interconnected. The microbubble-CD11b-inflammatory cell complex is successfully constructed by using the connection of a modified microbubble surface group and an activated CD11b molecule on the surface of the inflammatory cell, so the combination of the microbubble with an inflammatory cell in blood through the special CD11b molecule on the inflammatory cell is ensured, and the activation site of the inflammatory cell and blood vessel endothelial adherence and migration is reserved; and the acoustic radiation force is used to enhance the local concentration and the targeting adherence effect of the complex to realize the in-vivo display of the endothelial inflammatory activity in the atherosclerotic part in order to simulate the pathophysiological process of the inflammatory cell induced atherosclerosis, so the system has a great bionic meaning.

The present invention includes compositions and methods for regenerating glucose-responsive cells by ultrasound-targeted microbubble destruction in the pancreas, wherein the composition comprises a pre-assembled liposome-nucleic acid complex in contact with in and about a microbubble, wherein the pre-assembled liposome-nucleic acid complex comprises a NeuroD gene under the control of the promoter, wherein disruption of the microbubble in the pancreas at a target site delivers the nucleic acid into pancreas cells at the location of the ultrasound disruption, wherein cells that incorporate the nucleic acid express insulin in response to high blood glucose levels.

The invention belongs to the field of biomedical engineering, and more specifically, the invention relates to a new type of ultrasonic microbubble used as an immune adjuvant and vaccine carrier. Ultrasound microbubbles carrying vaccine antigens are synthesized by adhering the vaccine antigen material to the surface of the microbubbles and / or wrapping them in the microbubbles; when used, the microbubbles carrying the vaccine antigens are applied to the target tissue through the system and locally, and ultrasonic waves are used to destroy the target tissue. The microbubbles in the tissue area release vaccine antigen substances in a localized manner and enhance the immune activity of the antigens. It is expected to be developed into a new immune adjuvant and vaccine carrier, especially new adjuvants and carriers suitable for peptide vaccines, nucleic acid vaccines, viral and bacterial vaccines.

The invention provides a targeted nano-microbubble for treating small cell lung cancer, a preparation method and application thereof. Targeted nano-microbubbles include a lipid bimolecular shell and an inert gas wrapped inside the lipid bimolecular shell, and the anti-progastrin releasing peptide monoclonal antibody of small cell lung cancer and paclitaxel are connected to the lipid bimolecular shell, The average particle size of nano-microbubbles is 300-500nm. Preparation method: dipalmitolecithin, distearoylphosphatidylethanolamine, dipalmitophosphatidic acid and paclitaxel were completely dissolved in chloroform by film hydration method to prepare paclitaxel-containing liposomes, which are aimed at anti-progastrocytosis of small cell lung cancer The hormone-releasing peptide monoclonal antibody was opened with mercaptoethylamine, incubated with the liposome above to form a stable thioether bond, and then perfluoropropane gas was passed through, and the anti-monogastric antibody targeting small cell lung cancer was obtained by mechanical vibration. Secretin-releasing peptide monoclonal antibody targeting paclitaxel nanomicrobubbles. The targeted nanometer microbubble can be used in the preparation of medicines for treating small cell lung cancer.

The invention relates to a manganese dioxide and doxorubicin supported nanometer hydrogel and preparation and application thereof. The manganese dioxide and doxorubicin supported nanometr hydrogel isprepared by supporting manganese dioxide and drugs to poly-N-vinyl-epsilon-caprolactam nano hydrogel. The preparation method is simple, the product is easy to purify, and the cost is low. The nanometer hydrogel prepared by using the method is low in particle diameter, is uniformly distributed, and is high in water solubility, colloidal stability and biocompatibility. The nanometer hydrogel prepared by using the method can be used as a magnetic resonance imaging contrast agent, in the combination of an ultrasound-targeted microbubble destruction technology, proliferation of cancer cells can besignificantly inhibited, and the manganese dioxide and doxorubicin supported nanometer hydrogel has a potential application value in the field of tumor diagnosis and treatment.

The invention belongs to the biomedical engineering field, in particular relating to a novel targeted microbubble contrast agent. The microbubble contrast agent modified by sulfatides is synthesized by adding the sulfatides during the preparation process of microbubbles, and can be targetedly accumulated in a target tissue during the use to enhance the imaging effect of the target issue, and is expected to be developed into the novel targeted microbubble contrast agent.

The invention provides a path planning method based on UTMD algorithm. The path planning method based on the UTMD algorithm comprises the steps that S1, an optimized mathematical model of path planning is established; S21, an optimal solution search range of path planning is delineated; S2201, a plurality of microbubbles are released in the optimal solution search range; S2202, the initial maximumnumber of transferring is equal to M, the initial maximum number of differentiation is equal to L, and the initial maximum number of binding variation is equal to N; S2203, microbubble transferring is carried out; S2204, the step S2203 is repeated until the number of microbubble transferring is equal to M; S2205, a target MiRNAs is released; and S2206, transferring, differentiation and binding variation of the target are carried out until the number of transferring, the number of differentiation and the number of binding variation separately satisfy the convergence conditions of transferring,differentiation and binding variation, and an optimal solution set of path planning is obtained. The UTMD (targeted microbubble destruction) algorithm is used in the path planning method to considerthe slope of a road, path planning is optimized in real time in the three-dimensional space, the iterative calculation and search time in the path planning process are effectively reduced, a local optimal solution is prevented from appearing, and the optimization accuracy of path planning is improved.

The invention discloses a targeted microbubble loaded with NO and a preparation method thereof. The microbubble is a hollow liposome. The surface of the liposome is bonded with streptavidin, which iscoupled with a biotin modified C4d / C3d antibody. The liposome is filled with a mixed gas of NO / CO and polymer inert gas. According to the invention, the novel microbubble NO-MBC4d is successfully prepared, and the microbubble is utilized to successfully realize targeted and accurate treatment of graft AMR. The treatment process has high safety, and the microbubble has a good clinical application prospect.

The present invention includes compositions and methods for transforming cells into glucose- responsive, insulin-production cells using a construct that expresses betacellulin and PDXl, e.g., transforming pancreatic acinar cells using one or more expression vectors that expressed betacellulin and PDXl using ultrasound targeted microbubble destruction (UTMD).

The invention relates to the technical field of biology, and particularly discloses an iRGD magnetic targeting microbubble contrast agent and application thereof. The iRGD magnetic targeting microbubble contrast agent comprises magnetic iRGD targeting PLGA microbubbles and ferroferric oxide nanoparticles entrapped on the surfaces of the PLGA microbubbles. According to the iRGD magnetic targeting microbubble contrast agent and the application thereof, iRGD and the ferroferric oxide nanoparticles are loaded on the PLGA microbubbles together, the effect of targeting new capillaries through the PLGA microbubbles is further improved, ultrasonic / magnetic resonance bimodal imaging is achieved, and the process of endometrial angiogenesis change is observed advantageously.

The invention belongs to the field of medicines, and relates to a bionic lipid microbubble ultrasonic contrast agent constructed by cell membranes and a preparation method of the contrast agent. The preparation method comprises the following steps: firstly, separating cells; extracting cell membranes; ultrasonically vibrating the cell membranes and phospholipids to prepare liposomes of mixed cellmembranes and phospholipids; and finally, introducing gas into the liposomes, and performing mechanical vibration to prepare the targeted microbubble ultrasonic contrast agent. According to the bioniclipid microbubble ultrasound contrast agent disclosed by the invention, the biological characteristics of the cell membranes are integrated into the ultrasound contrast agent, so that the applicationrange of the traditional microbubble ultrasound contrast agent is broken through. The preparation method of the bionic liposome has the advantages of natural targeting and easy clinical transformation.

The present invention includes compositions and methods for transforming cells into glucose-responsive, insulin-production cells using a construct that expresses betacellulin and PDX1, e.g., transforming pancreatic acinar cells using one or more expression vectors that expressed betacellulin and PDX1 using ultrasound targeted microbubble destruction (UTMD).

The invention relates to a monitoring device for cell microdamage induction and a bright field monitoring method.The monitoring device comprises a sample introduction unit, an ultrasonic generation unit, an optical detection unit and a processing unit, and the processing unit inputs a bright field image into a first neural network; and performing re-optimization processing on the initial segmentation image about the cells and the microbubbles obtained by the feature segmentation processing to obtain a cell segmentation image and a microbubble segmentation image, performing feature extraction of target cells on the cell segmentation image, and performing feature extraction of target microbubbles on the microbubble segmentation image. And obtaining a cell microdamage characteristic parameter, a microbubble microdamage characteristic parameter and a joint microdamage characteristic parameter, inputting the microdamage characteristic parameters into a second neural network, and carrying out classification processing on microdamage characteristics to obtain a classification result of a target cell microdamage degree. According to the technical scheme, a novel cell microdamage monitoring mode is provided, and the classification result of the target cell microdamage degree can be obtained through accurate and refined analysis.

Embodiments of the disclosure concern methods and compositions for treatment of a cardiac-related medical condition. In particular embodiments, ANGPTL8 is provided to an individual in need thereof for the treatment or prevention of a cardiac-related medical condition. In certain cases, ANGPTL8 is provided to an individual with cardiomyopathy, such as Adriamycin-induced cardiomyopathy, using ultrasound-targeted microbubble destruction.

The invention relates to a method for preparing ultrasound-assisted sPD1-loaded microbubbles targeting CD133. The method specifically comprises the steps that PE labeled streptavidin is added dropwiseinto biotinylated lipid microbubbles for incubation, then a biotinylated CD133 antibody is added, and after the incubation is completed, centrifugation is carried out to obtain the microbubbles targeting CD133; the obtained microbubbles targeting CD133 and sPD1 plasmids are incubated at room temperature, then washed with PBS and centrifuged to obtain the sPD1-loaded microbubbles targeting CD133.The sPD1-loaded lipid microbubbles targeting CD133 are used for preparing drugs for inhibiting cervical cancer transplantation tumors, results show that the sPD1-loaded lipid microbubbles targeting CD133 have a higher antitumor effect, and the volume inhibition rate and body weight inhibition rate of the sPD1-loaded lipid microbubbles targeting CD133 are 78.01% and 72.25% respectively.

The invention discloses a preparation method and application of double-ligand-carrying interleukin ultrasonic targeting microbubbles. The preparation method of the double-ligand-carrying interleukin ultrasonic targeting microbubbles comprises the following steps: (1) detecting the binding rates of biotinylated IL-6 monoclonal antibodies and IL-8 monoclonal antibodies with different doses and TargestarSA microbubbles by virtue of a flow cytometry; (2) preparing ultrasonic microbubbles carrying double antibodies of IL-6 and IL-8: adding 100 [mu]g of an IL-6 antibody labeled by biotin and fluorescence (FITC) and 100 [mu]g of an IL-8 antibody labeled by biotin and fluorescence (Rhodamin) into 1 ml of streptavidin-coated Targestar SA microbubble in a vial by using a trace sampling gun, performing incubating at room temperature until the freeze-dried powder is not completely dispersed, so as to obtain a uniform white emulsion suspension, namely, to obtain the ultrasonic targeting microbubbles carrying IL-6 and IL-8 double antibodies.

Embodiments of the disclosure provide methods and / or compositions useful for an individual in need of treatment of a cardiac-related medical condition. In particular cases, GLP-1 is employed in a ultrasound targeted microbubble destruction (UTMD) system for delivery to cardiac tissue, thereby stimulating myocardial regeneration and, in at least some cases, reversal of cardiomyopathy.

The invention relates to the technical field of ultrasonic nerve stimulation, and provides an ion channel targeted microbubble as well as a preparation method and application thereof. The ion channel targeted ultrasonic microbubble comprises a shell membrane and a biological inert gas, the biological inert gas is sealed in a capsule enclosed by the shell membrane, and the outer surface of the shell membrane is combined with an ion channel antibody. According to the ion channel targeted microbubble provided by the invention, through targeted binding of the ion channel antibody and the ion channel, ultrasonic energy for opening the ion channel by ultrasonic radiation force can be reduced, and extracellular ions are promoted to flow into cells, so that the sensitivity of ultrasonic nerve stimulation response is enhanced.

The invention discloses a short peptide used for cancer targeted therapy, ultrasound-responsive nano drug-carrying microbubbles based on the short peptide and its application, and belongs to the technical field of biomedicine. The short peptide disclosed in the present invention is a novel short peptide composed of 9 amino acids. At the same time, the present invention adopts the principle of ultrasonic irradiation combined with drug-loaded targeting microbubbles to establish a molecular targeting method for neovascularization based on the novel short peptide. Ultrasound-responsive nano drug-loaded microbubbles, carboxylated PEG termini on the surface of drug-loaded nanoparticles and NH of short peptide terminal amino acids 2 Combining to form an amide bond, the connection method of the terminal amino group reduces the impact on the conformation and activity of the novel polypeptide, and protects the recognition and binding ability of the novel polypeptide and the highly expressed Dll4 ligand on the surface of vascular endothelial cells as much as possible. Compared with the previous hD4R peptide, the combination of the active ingredients in it with nano drug delivery system and ultrasound will provide a new and efficient mode of anti-tumor angiogenesis.